SEC Form 4 · accession 0001193125-26-403097
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Robert Ajer
Director
Period of report
Sep 23, 2026
Accepted (ET)
Sep 25, 2026 · 8:18 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Sep 23, 2026 | A | 2,000 | $0.00 | A | 4,277 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF4 | $57.66 | Sep 23, 2026 | A | 4,000 | A | — | Sep 22, 2034 | Common Stock | 4,000 | 4,000 | D |
Explanation of responses
- F1Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
- F2This RSU award vests in full, one year following September 23, 2026.
- F3On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
- F4This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.